These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 10199464

  • 1. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication.
    Patt YZ, Hoque A, Roh M, Ellis L, Lozano R, Carrasco CH, Charnsangavej C, Cleary K.
    Am J Clin Oncol; 1999 Apr; 22(2):209-13. PubMed ID: 10199464
    [Abstract] [Full Text] [Related]

  • 2. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
    Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ.
    J Natl Cancer Inst; 2005 Oct 19; 97(20):1532-8. PubMed ID: 16234567
    [Abstract] [Full Text] [Related]

  • 3. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.
    Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN.
    Cancer; 2013 Sep 15; 119(18):3334-42. PubMed ID: 23821538
    [Abstract] [Full Text] [Related]

  • 4. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
    Akçali Z, Akin E, Ozyilkan O.
    Cancer; 2002 Nov 01; 95(9):2038-9; author reply 2039. PubMed ID: 12404300
    [No Abstract] [Full Text] [Related]

  • 5. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.
    Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K.
    Int J Clin Oncol; 2011 Jun 01; 16(3):221-9. PubMed ID: 21132451
    [Abstract] [Full Text] [Related]

  • 6. Effective treatment for advanced hepatocellular carcinoma with portal venous invasion using a combination therapy of intra-arterial 5-fluorouracil and subcutaneous pegylated-interferon-alpha-2b.
    Mawatari H, Kirikoshi H, Yoneda M, Higurashi T, Fujita K, Saito S, Inamori M, Takahashi H, Abe Y, Kubota K, Nakajima A.
    Hepatogastroenterology; 2008 Jun 01; 55(86-87):1776-7. PubMed ID: 19102391
    [Abstract] [Full Text] [Related]

  • 7. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study.
    Vitale FV, Romeo P, Vasta F, Panebianco V, Calì S, Rotondo S, Ferraù F, La Greca M.
    Anticancer Res; 2007 Jun 01; 27(6B):4077-81. PubMed ID: 18225574
    [Abstract] [Full Text] [Related]

  • 8. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma.
    Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K.
    Oncology; 1998 Jun 01; 55(1):39-47. PubMed ID: 9428374
    [Abstract] [Full Text] [Related]

  • 9. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC.
    Scand J Gastroenterol; 2009 Jun 01; 44(12):1477-86. PubMed ID: 19958061
    [Abstract] [Full Text] [Related]

  • 10. Systemic therapy for hepatocellular carcinoma.
    Leung TW, Johnson PJ.
    Semin Oncol; 2001 Oct 01; 28(5):514-20. PubMed ID: 11685744
    [Abstract] [Full Text] [Related]

  • 11. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.
    Yin XY, Lü MD, Liang LJ, Lai JM, Li DM, Kuang M.
    World J Gastroenterol; 2005 Apr 28; 11(16):2526-9. PubMed ID: 15832431
    [Abstract] [Full Text] [Related]

  • 12. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
    Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ.
    Clin Cancer Res; 1999 Jul 28; 5(7):1676-81. PubMed ID: 10430068
    [Abstract] [Full Text] [Related]

  • 13. [Recent progress in chemotherapy for hepatocellular carcinoma].
    Sakon M, Nagano H, Monden M.
    Nihon Naika Gakkai Zasshi; 2004 Aug 10; 93(8):1660-5. PubMed ID: 15384699
    [No Abstract] [Full Text] [Related]

  • 14. [The progress of hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
    Noda T, Nagano H, Wada H, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Ohsuga K, Kim T, Tomoda K, Nakamura H, Monden M.
    Gan To Kagaku Ryoho; 2006 Sep 10; 33(9):1221-5. PubMed ID: 16969014
    [Abstract] [Full Text] [Related]

  • 15. [Hepatic arterial infusion chemotherapy combined with interferon-alpha for hepatocellular carcinoma].
    Nagano H, Eguchi H, Sakon M, Monden M.
    Nihon Rinsho; 2001 Oct 10; 59 Suppl 6():748-52. PubMed ID: 11762050
    [No Abstract] [Full Text] [Related]

  • 16. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
    Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, Johnson PJ.
    Cancer; 2002 Jan 15; 94(2):421-7. PubMed ID: 11905412
    [Abstract] [Full Text] [Related]

  • 17. Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma.
    Okita K, Yamasaki T, Hamabe S, Saeki I, Harima Y, Terai S, Sakaida I.
    Hepatogastroenterology; 2012 Jan 15; 59(114):533-7. PubMed ID: 22353519
    [Abstract] [Full Text] [Related]

  • 18. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
    Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, Kodama H, Shirakawa H, Kawakami Y, Takahashi S, Toyota N, Ito K, Chayama K.
    Liver Int; 2007 Nov 15; 27(9):1209-16. PubMed ID: 17919232
    [Abstract] [Full Text] [Related]

  • 19. [Hepatic arterial infusion chemotherapy (HAIC)--hepatocellular carcinoma].
    Osuga K, Murakami T, Nakata S, Tomoda K, Nagano H, Monden M, Nakamura H.
    Gan To Kagaku Ryoho; 2004 Dec 15; 31(13):2114-7. PubMed ID: 15628754
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Patt YZ, Hoque A, Lozano R, Pozdur R, Chase J, Carrasco H, Chuang V, Delpassand ES, Ellis L, Curley S, Roh M, Jones DV.
    J Clin Oncol; 1997 Apr 15; 15(4):1432-8. PubMed ID: 9193336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.